GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

Archives of Biochemistry and Biophysics
Brian D GreenDavid J Grieve

Abstract

Increasing evidence from both clinical and experimental studies indicates that the insulin-releasing hormone, glucagon-like peptide-1 (GLP-1) may exert additional protective/reparative effects on the cardiovascular system. The aim of this study was to examine vasorelaxant effects of GLP-1(7-36)amide, three structurally-related peptides and a non-peptide GLP-1 agonist in rat aorta. Interestingly, all GLP-1 compounds, including the established GLP-1 receptor antagonist, exendin (9-39) caused concentration-dependent relaxation. Mechanistic studies employing hyperpolarising concentrations of potassium or glybenclamide revealed that these relaxant effects are mediated via specific activation of ATP-sensitive potassium channels. Further experiments using a specific membrane-permeable cyclic AMP (cAMP) antagonist, and demonstration of increased cAMP production in response to GLP-1 illustrated the critical importance of this pathway. These data significantly extend previous observations suggesting that GLP-1 may modulate vascular function, and indicate that this effect may be mediated by the GLP-1 receptor. However, further studies are required in order to establish whether GLP-1 related agents may confer additional cardiovascular bene...Continue Reading

Associated Clinical Trials

References

Aug 22, 1997·The Journal of Biological Chemistry·C Montrose-RafizadehJ Eng
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker

❮ Previous
Next ❯

Citations

Aug 11, 2012·Current Atherosclerosis Reports·Kyung-Sun HeoJun-ichi Abe
Jan 6, 2011·Diabetes, Obesity & Metabolism·P AnagnostisD P Mikhailidis
Nov 30, 2012·American Journal of Physiology. Endocrinology and Metabolism·Zhenhua DongZhenqi Liu
Aug 31, 2013·Diabetology & Metabolic Syndrome·Asfandyar Sheikh
Jan 21, 2012·The Review of Diabetic Studies : RDS·Michael Lehrke, Nikolaus Marx
Aug 9, 2013·The Journal of Endocrinology·Franca S Angeli, Richard P Shannon
Jun 3, 2014·Reviews in Endocrine & Metabolic Disorders·Adam G GoodwillJohnathan D Tune
Mar 21, 2012·Herz·M Lehrke, N Marx
Aug 8, 2015·International Journal of Molecular Sciences·Sebastian StevenAndreas Daiber
Jan 13, 2011·Current Medical Research and Opinion·Jens Juul HolstEsther Nathanson
Dec 5, 2015·Diabetes, Obesity & Metabolism·Marcel H A MuskietDaniël H van Raalte
Dec 4, 2013·Trends in Cardiovascular Medicine·Andrew J KwokIan Sabir
Mar 15, 2011·Vascular Pharmacology·Zubair ShahSanjay Rajagopalan
Aug 6, 2010·Trends in Cardiovascular Medicine·Marek TreimanJan Skov Jensen
Dec 19, 2009·Trends in Endocrinology and Metabolism : TEM·Eva Tomas, Joel F Habener
Jun 30, 2009·Peptides·Kristopher C DozierGregory P Victorino
Dec 21, 2010·Cardiovascular Therapeutics·Theodore Okerson, Robert J Chilton
Jul 30, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mona K Tawfik, Magda I Mohamed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Homeostasis

Cardiovascular regulation and homeostasis is important in maintaining health and dysfunction may lead to cardiovascular diseases. Nitric oxide and vascular endothelium are one of many molecules involved in the homeostatic mechanism. Here is the latest research on cardiovascular homeostasis.